Trader Ionis Pharmaceuticals, Inc. - IONS CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Écart | 0.06 | ||||||||
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.024068% | ||||||||
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.001846% | ||||||||
Durée des frais en overnight | 21:00 (UTC) | ||||||||
Quantité minimale négociée | 1 | ||||||||
Devise | USD | ||||||||
Marge | 20% | ||||||||
Bourse | United States of America | ||||||||
Commission sur la négociation | 0% |
*Information provided by Capital.com
Fermeture précédente* | 35.16 |
Ouvert* | 35.15 |
Variation sur 1 an* | -3.01% |
Fourchette du jour* | 33.46 - 35.31 |
Fourchette sur 52 semaines | 31.46-48.82 |
Volume moyen (10 jours) | 973.89K |
Volume moyen (3 mois) | 19.26M |
Capitalisation boursière | 5.09B |
Ratio C/B | -100.00K |
Actions en circulation | 142.95M |
Revenu | 587.37M |
EPS | -1.90 |
Dividende (rendement en %) | N/A |
Bêta | 0.54 |
Prochaine date de publication des résultats | May 2, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Clôture | Change | Change (%) | Ouverture | High | Low |
---|---|---|---|---|---|---|
Mar 22, 2023 | 35.16 | 0.14 | 0.40% | 35.02 | 35.57 | 34.55 |
Mar 21, 2023 | 35.47 | 0.53 | 1.52% | 34.94 | 35.75 | 34.67 |
Mar 20, 2023 | 35.45 | -0.31 | -0.87% | 35.76 | 36.04 | 35.03 |
Mar 17, 2023 | 35.04 | 0.77 | 2.25% | 34.27 | 35.20 | 33.70 |
Mar 16, 2023 | 34.86 | 1.50 | 4.50% | 33.36 | 35.00 | 33.36 |
Mar 15, 2023 | 34.15 | 0.99 | 2.99% | 33.16 | 34.18 | 32.63 |
Mar 14, 2023 | 33.74 | 0.43 | 1.29% | 33.31 | 33.88 | 32.39 |
Mar 13, 2023 | 33.50 | 0.15 | 0.45% | 33.35 | 34.65 | 33.35 |
Mar 10, 2023 | 33.91 | 0.05 | 0.15% | 33.86 | 34.75 | 33.52 |
Mar 9, 2023 | 34.62 | -0.80 | -2.26% | 35.42 | 35.72 | 34.28 |
Mar 8, 2023 | 35.62 | 0.12 | 0.34% | 35.50 | 35.83 | 35.15 |
Mar 7, 2023 | 35.65 | -0.22 | -0.61% | 35.87 | 36.14 | 35.49 |
Mar 6, 2023 | 36.12 | -0.10 | -0.28% | 36.22 | 36.63 | 35.81 |
Mar 3, 2023 | 36.45 | 0.91 | 2.56% | 35.54 | 36.71 | 35.01 |
Mar 2, 2023 | 35.66 | 0.39 | 1.11% | 35.27 | 35.84 | 35.07 |
Mar 1, 2023 | 35.89 | 0.28 | 0.79% | 35.61 | 36.31 | 34.93 |
Feb 28, 2023 | 35.71 | 0.62 | 1.77% | 35.09 | 36.58 | 34.60 |
Feb 27, 2023 | 36.08 | 0.24 | 0.67% | 35.84 | 36.38 | 34.90 |
Feb 24, 2023 | 35.56 | -0.50 | -1.39% | 36.06 | 36.16 | 35.25 |
Feb 23, 2023 | 36.50 | 0.65 | 1.81% | 35.85 | 36.82 | 34.92 |
Ionis Pharmaceuticals, Inc. Events
Heure (UTC) (UTC) | Pays | Événement |
---|---|---|
No events scheduled |
- Annuel
- Trimestriel
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Revenu total | 810.456 | 729.264 | 1122.6 | 599.674 | 514.179 |
Revenu | 810.456 | 729.264 | 1122.6 | 599.674 | 514.179 |
Coût des recettes, total | 10.842 | 11.947 | 4.384 | 1.82 | 0 |
Résultat brut | 799.614 | 717.317 | 1118.21 | 597.854 | 514.179 |
Total des frais d'exploitation | 849.269 | 901.346 | 822.912 | 661.046 | 490.821 |
Total des frais de vente/Généraux/Admin | 170.947 | 332.222 | 286.644 | 244.622 | 108.488 |
Recherche et développement | 634.953 | 526.877 | 465.688 | 414.604 | 374.644 |
Charges (revenus) inhabituelles | 32.527 | 30.3 | 66.196 | 0 | 7.689 |
Produits d'exploitation | -38.813 | -172.082 | 299.687 | -61.372 | 23.358 |
Produits (charges) d'intérêts, nets Hors exploitation | 10.798 | 37.592 | 39.765 | -14.602 | -36.573 |
Autres, nets | -1.133 | -0.062 | -0.686 | -0.182 | -3.548 |
Résultat net avant impôts | -29.148 | -134.552 | 338.766 | -76.156 | -16.763 |
Résultat net après impôts | -28.597 | -479.743 | 287.259 | -117.115 | 96.517 |
Intérêts minoritaires | 0 | 35.48 | -9.116 | 58.756 | 11.129 |
Résultat net avant éléments extra | -28.597 | -444.263 | 278.143 | -58.359 | 107.646 |
Résultat net | -28.597 | -444.263 | 278.143 | 273.741 | 0.346 |
Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -28.597 | -444.263 | 278.143 | -58.359 | 107.646 |
Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -28.597 | -444.263 | 278.143 | 273.741 | 0.346 |
Ajustement pour dilution | 0 | 0 | |||
Résultat net dilué | -28.597 | -444.263 | 278.143 | 273.741 | 0.346 |
Moyenne pondérée des actions diluées | 141.021 | 139.612 | 153.164 | 134.056 | 126.098 |
BPA dilué hors éléments extraordinaires | -0.20279 | -3.18213 | 1.81598 | -0.43533 | 0.85367 |
BPA dilué normalisé | -0.05286 | -3.04106 | 2.18246 | -0.43533 | 0.8933 |
Total des éléments extraordinaires | 332.1 | -107.3 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Revenu total | 141.919 | 440.006 | 133.093 | 125.75 | 111.607 |
Revenu | 141.919 | 440.006 | 133.093 | 125.75 | 111.607 |
Coût des recettes, total | 4.17 | 2.226 | 3.079 | 2.958 | 2.578 |
Résultat brut | 137.749 | 437.78 | 130.014 | 122.792 | 109.029 |
Total des frais d'exploitation | 199.423 | 219.401 | 218.942 | 207.346 | 203.578 |
Total des frais de vente/Généraux/Admin | 34.127 | 37.6 | 31.093 | 56.455 | 61.199 |
Recherche et développement | 161.126 | 179.575 | 184.77 | 139.306 | 139.801 |
Produits d'exploitation | -57.504 | 220.605 | -85.849 | -81.596 | -91.971 |
Produits (charges) d'intérêts, nets Hors exploitation | -6.754 | 4.788 | 2.545 | 1.237 | 2.229 |
Autres, nets | 0.187 | -0.477 | -0.469 | -0.189 | 0.003 |
Résultat net avant impôts | -64.071 | 224.916 | -83.773 | -80.548 | -89.739 |
Résultat net après impôts | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
Intérêts minoritaires | 0 | 0 | 0 | 0 | |
Résultat net avant éléments extra | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
Résultat net | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
Résultat net dilué | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
Moyenne pondérée des actions diluées | 141.599 | 141.21 | 141.139 | 140.962 | 140.77 |
BPA dilué hors éléments extraordinaires | -0.46021 | 1.59063 | -0.58429 | -0.57374 | -0.63841 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA dilué normalisé | -0.46021 | 1.59063 | -0.58429 | -0.53396 | -0.63841 |
Charges (revenus) inhabituelles | 0 | 0 | 8.627 |
- Annuel
- Trimestriel
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total de l'actif à court terme | 2345.05 | 2130.71 | 2720.6 | 2207.89 | 1168.73 |
Espèces et placements à court terme | 2114.97 | 1892.38 | 2499.54 | 2084.07 | 1022.72 |
Trésorerie et équivalents | 869.191 | 397.664 | 683.287 | 278.82 | 129.63 |
Investissements à court terme | 1245.78 | 1494.71 | 1816.26 | 1805.25 | 893.085 |
Total des créances, nettes | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Accounts Receivable - Trade, Net | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Total Inventory | 24.806 | 21.965 | 18.18 | 8.582 | 9.982 |
Other Current Assets, Total | 143.374 | 140.163 | 139.839 | 102.473 | 73.082 |
Total Assets | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Property/Plant/Equipment, Total - Net | 196.069 | 181.077 | 166.251 | 132.16 | 121.907 |
Property/Plant/Equipment, Total - Gross | 298.722 | 240.264 | 193.634 | 209.583 | |
Accumulated Depreciation, Total | -102.653 | -74.013 | -61.474 | -87.676 | |
Intangibles, Net | 29.005 | 27.937 | 25.674 | 24.032 | 22.004 |
Other Long Term Assets, Total | 41.567 | 50.034 | 320.59 | 303.706 | 10.129 |
Total Current Liabilities | 240.55 | 598.898 | 273.005 | 280.294 | 243.612 |
Accounts Payable | 11.904 | 17.199 | 16.067 | 28.66 | 24.886 |
Accrued Expenses | 129.97 | 155.889 | 106.152 | 77.629 | 91.769 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.926 | 316.11 | 13.749 | 1.621 | |
Other Current Liabilities, Total | 97.75 | 109.7 | 150.786 | 160.256 | 125.336 |
Total Liabilities | 1839.95 | 1646.47 | 1762.02 | 1619.7 | 1041.76 |
Total Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Capital Lease Obligations | |||||
Other Liabilities, Total | 371.379 | 424.046 | 505.26 | 567.359 | 108.026 |
Total Equity | 771.737 | 743.282 | 1471.09 | 1048.08 | 281.013 |
Common Stock | 0.141 | 0.14 | 0.14 | 0.138 | 0.125 |
Additional Paid-In Capital | 1964.17 | 1895.52 | 2203.78 | 2047.25 | 1553.68 |
Retained Earnings (Accumulated Deficit) | -1159.9 | -1131.31 | -707.534 | -967.293 | -1241.03 |
Other Equity, Total | -32.668 | -21.071 | -25.29 | -32.016 | -31.759 |
Total Liabilities & Shareholders’ Equity | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Total Common Shares Outstanding | 141.21 | 140.366 | 140.34 | 137.929 | 124.976 |
Minority Interest | 213.453 | 139.081 | 84.267 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total de l'actif à court terme | 2253.12 | 2345.05 | 2155.74 | 2238.42 | 1989.42 |
Espèces et placements à court terme | 2052.39 | 2114.97 | 1987.1 | 2059.27 | 1819.99 |
Trésorerie et équivalents | 542.513 | 869.191 | 632.953 | 565.119 | 414.155 |
Investissements à court terme | 1509.88 | 1245.78 | 1354.15 | 1494.15 | 1405.84 |
Total des créances, nettes | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Accounts Receivable - Trade, Net | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Total Inventory | 24.032 | 24.806 | 22.93 | 24.099 | 22.199 |
Other Current Assets, Total | 150.577 | 143.374 | 136.643 | 131.045 | 123.827 |
Total Assets | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Property/Plant/Equipment, Total - Net | 177.724 | 196.069 | 180.144 | 179.316 | 180.413 |
Intangibles, Net | 29.295 | 29.005 | 30.038 | 29.373 | 28.795 |
Other Long Term Assets, Total | 58.949 | 41.567 | 48.971 | 49.962 | 49.925 |
Total Current Liabilities | 228.45 | 240.55 | 279.778 | 293.825 | 295.105 |
Accounts Payable | 16.125 | 11.904 | 8.357 | 14.658 | 9.506 |
Accrued Expenses | 115.781 | 129.97 | 108.001 | 105.372 | 108.029 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.206 | 0.926 | 65.045 | 69.848 | 69.504 |
Other Current Liabilities, Total | 92.338 | 97.75 | 98.375 | 103.947 | 108.066 |
Total Liabilities | 1809.52 | 1839.95 | 1884.36 | 1914.4 | 1567.99 |
Total Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Other Liabilities, Total | 333.138 | 371.379 | 362.887 | 379.874 | 401.966 |
Total Equity | 709.574 | 771.737 | 530.536 | 582.674 | 680.564 |
Common Stock | 0.142 | 0.141 | 0.141 | 0.141 | 0.141 |
Additional Paid-In Capital | 1983.08 | 1964.17 | 1942.35 | 1910.38 | 1925.8 |
Retained Earnings (Accumulated Deficit) | -1225.07 | -1159.9 | -1384.52 | -1302.05 | -1221.18 |
Other Equity, Total | -48.578 | -32.668 | -27.437 | -25.796 | -24.203 |
Total Liabilities & Shareholders’ Equity | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Total Common Shares Outstanding | 141.753 | 141.21 | 141.184 | 141.022 | 140.924 |
- Annuel
- Trimestriel
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Revenu net/Ligne de départ | -28.597 | -479.743 | 287.259 | 214.985 | -10.783 |
Liquidités provenant des activités d'exploitation | 30.799 | 35.892 | 345.627 | 602.906 | 174.149 |
Liquidités provenant des activités d'exploitation | 15.487 | 13.365 | 12.54 | 10.706 | 6.708 |
Amortization | 2.352 | 2.064 | 1.912 | 1.822 | 1.641 |
Deferred Taxes | 0 | 341.729 | 0.911 | -290.516 | 0 |
Éléments non monétaires | 155.375 | 232.032 | 211.806 | 166.484 | 139.539 |
Intérêts payés en espèces | 4.778 | 6.247 | 9.87 | 9.592 | 8.035 |
Variation du fonds de roulement | -113.818 | -73.555 | -168.801 | 499.425 | 37.044 |
Flux de trésorerie liés aux activités d'investissement | 194.906 | 274.477 | -41.274 | -929.563 | -358.291 |
Dépenses d'investissement | -11.955 | -35.12 | -30.905 | -13.608 | -34.764 |
Autres éléments de flux de trésorerie d'investissement, total | 206.861 | 309.597 | -10.369 | -915.955 | -323.527 |
Flux de trésorerie provenant des activités de financement | 245.933 | -596.609 | 100.021 | 475.865 | 229.087 |
Éléments de flux de trésorerie de financement | -168.954 | -558.097 | -138.354 | 0 | 47.963 |
Émission (remboursement) d'actions, nette | 101.317 | -38.512 | 141.375 | 475.865 | 205.106 |
Émission (remboursement) de la dette, nette | 313.57 | 0 | 97 | 0 | -23.982 |
Variation nette de la trésorerie | 471.527 | -285.623 | 404.467 | 149.19 | 44.945 |
Cash Taxes Paid | 0.038 | 25.855 | 9.041 | 0 | |
Effets de change | -0.111 | 0.617 | 0.093 | -0.018 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -65.165 | -28.597 | -253.21 | -170.744 | -89.869 |
Cash From Operating Activities | -31.65 | 30.799 | -172.888 | -117.314 | -54.662 |
Cash From Operating Activities | 3.701 | 15.487 | 11.665 | 7.951 | 3.917 |
Amortization | 0.592 | 2.352 | 1.74 | 1.137 | 0.544 |
Deferred Taxes | 0 | 0 | 0 | 0 | |
Non-Cash Items | 32.983 | 155.375 | 125.535 | 88.261 | 43.346 |
Cash Taxes Paid | 0.002 | 0.038 | 0.003 | 0.002 | |
Cash Interest Paid | 0.594 | 4.778 | 3.527 | 2.866 | 0.594 |
Changes in Working Capital | -3.761 | -113.818 | -58.618 | -43.919 | -12.6 |
Cash From Investing Activities | -287.549 | 194.906 | 99.797 | -22.174 | 78.856 |
Capital Expenditures | -2.705 | -11.955 | -9.453 | -6.13 | -1.772 |
Other Investing Cash Flow Items, Total | -284.844 | 206.861 | 109.25 | -16.044 | 80.628 |
Cash From Financing Activities | -7.325 | 245.933 | 308.423 | 306.965 | -7.577 |
Financing Cash Flow Items | -9.173 | -168.954 | -168.43 | -167.966 | -15.337 |
Issuance (Retirement) of Stock, Net | 1.848 | 101.317 | 101.316 | 99.394 | 7.76 |
Foreign Exchange Effects | -0.154 | -0.111 | -0.043 | -0.022 | -0.126 |
Net Change in Cash | -326.678 | 471.527 | 235.289 | 167.455 | 16.491 |
Issuance (Retirement) of Debt, Net | 313.57 | 375.537 | 375.537 |
Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 14.9052 | 21307519 | 16360 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.4574 | 13519789 | 736550 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 8.1692 | 11678259 | 521564 | 2022-12-31 | MED |
Bellevue Asset Management AG | Investment Advisor | 6.8161 | 9743900 | 280500 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.986 | 7127720 | 135266 | 2022-12-31 | LOW |
ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 3.7954 | 5425642 | -348250 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.9511 | 4218729 | 457774 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.9049 | 4152607 | -508999 | 2022-12-31 | LOW |
Tweedy, Browne Company LLC | Investment Advisor | 2.4771 | 3541136 | 818148 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 1.8702 | 2673538 | -1039569 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.408 | 2012723 | 111580 | 2022-12-31 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.3946 | 1993600 | 1224700 | 2022-12-31 | LOW |
Camber Capital Management LP | Hedge Fund | 1.3466 | 1925000 | 0 | 2022-12-31 | MED |
First Trust Advisors L.P. | Investment Advisor | 1.2458 | 1780933 | -296327 | 2022-12-31 | LOW |
Macquarie Investment Management | Investment Advisor | 1.0435 | 1491687 | 657646 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.907 | 1296647 | 465428 | 2022-12-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.8788 | 1256268 | 53922 | 2022-12-31 | LOW |
Deep Track Capital LP | Hedge Fund | 0.8435 | 1205773 | 1205773 | 2022-12-31 | MED |
Renaissance Technologies LLC | Hedge Fund | 0.8246 | 1178814 | 311100 | 2022-12-31 | HIGH |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7966 | 1138714 | 15634 | 2022-12-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group500K+
Tradeurs
92K+
Clients actifs par mois
$53M+
Volume d'investissement par mois
$30M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ionis Pharmaceuticals Company profile
À propos de Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. est engagée dans la découverte et le développement de thérapies ciblées par l'acide ribonucléique (ARN). La société se concentre principalement sur ses franchises cardiovasculaires et neurologiques. Ses produits comprennent SPINRAZA, TEGSEDI et WAYLIVRA. SPINRAZA est destiné au traitement des patients de tous âges atteints d'amyotrophie spinale (SMA), une maladie génétique progressive, débilitante et souvent mortelle. TEGSEDI est destiné au traitement des patients atteints de polyneuropathie causée par l'amylose héréditaire à transthyrétine (TTR) (hATTR), une maladie débilitante, progressive et mortelle. WAYLIVRA est un médicament antisens indiqué comme adjuvant au régime alimentaire chez les patients adultes. La société a plus de six médicaments en études de phase III pour huit indications, dont Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) et Tofersen (SOD1). Ses médicaments cardiovasculaires en développement comprennent Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen et IONIS-AGT-LRx.
Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 500 000 traders du monde entier qui ont choisi de trader avec Capital.com